Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the thirteen research firms that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $28.50.
TVTX has been the topic of a number of recent research reports. Evercore ISI initiated coverage on Travere Therapeutics in a research report on Wednesday, September 6th. They set an “outperform” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on Travere Therapeutics in a report on Friday, July 21st. They set an “overweight” rating and a $26.00 price objective on the stock. Canaccord Genuity Group decreased their price objective on Travere Therapeutics from $37.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, July 18th. Piper Sandler decreased their price objective on Travere Therapeutics from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, August 18th. Finally, HC Wainwright decreased their price objective on Travere Therapeutics from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Monday, August 7th.
Insider Buying and Selling
Hedge Funds Weigh In On Travere Therapeutics
Several large investors have recently modified their holdings of TVTX. Huntington National Bank raised its stake in shares of Travere Therapeutics by 57.8% during the second quarter. Huntington National Bank now owns 1,943 shares of the company’s stock valued at $30,000 after acquiring an additional 712 shares during the last quarter. US Bancorp DE raised its stake in Travere Therapeutics by 1,372.3% during the first quarter. US Bancorp DE now owns 1,487 shares of the company’s stock worth $38,000 after buying an additional 1,386 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Travere Therapeutics by 551.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,527 shares of the company’s stock worth $39,000 after buying an additional 2,139 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in Travere Therapeutics by 21.7% during the second quarter. Ameritas Investment Partners Inc. now owns 6,016 shares of the company’s stock worth $92,000 after buying an additional 1,074 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Travere Therapeutics by 92.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,053 shares of the company’s stock worth $93,000 after buying an additional 2,914 shares during the last quarter.
Travere Therapeutics Price Performance
Travere Therapeutics stock opened at $13.41 on Tuesday. The company has a debt-to-equity ratio of 3.23, a current ratio of 3.99 and a quick ratio of 3.86. Travere Therapeutics has a one year low of $12.57 and a one year high of $26.84. The company’s fifty day moving average price is $14.84 and its two-hundred day moving average price is $17.37.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($1.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.03. Travere Therapeutics had a negative net margin of 136.00% and a negative return on equity of 273.80%. The company had revenue of $59.70 million during the quarter, compared to analysts’ expectations of $53.93 million. As a group, analysts anticipate that Travere Therapeutics will post -4.59 earnings per share for the current year.
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.
- Five stocks we like better than Travere Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- 3 Small Caps With Big Return Potential
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How to Invest in Electric Cars
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.